Lynn Kramer, MD, FAAN: BAN2401 Phase IIb Clinical Study Results скачать в хорошем качестве

Lynn Kramer, MD, FAAN: BAN2401 Phase IIb Clinical Study Results

Read more: https://www.neurologylive.com/confere... At the 2018 Alzheimer’s Association International Conference in Chicago, Illinois, Lynn Kramer, MD, FAAN, Chief Clinical Officer and Chief Medical Officer at Eisai, presented 18-month data from the BAN2401 phase IIb clinical study, Study 201, that suggest BAN2401 may slow the pace of cognitive decline in Alzheimer patients and reverse the buildup of amyloid plaques thought to drive the disease’s neurodegeneration. Though the trial failed to meet the study’s primary endpoint at 12 months, Kramer reported additional results on several of the trial’s secondary outcomes like reduction of amyloid plaques and improvement of cognition and function, though the trial was not intended to demonstrate efficacy in cognitive outcomes.